KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) announced today it has received allowance of its U.S. patent application, protecting diagnostic uses of a new class of radiochemical agents related to its therapeutic product PV-10, from the United States Patent and Trademark Office (USPTO).
